Español
India
Italiano
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Español
India
Italiano
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Replimune Group
(NASDAQ:REPL)
Intraday
$7.11
1.55
[27.88%]
After-Hours
$7.11
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$7.11
1.55
[27.88%]
At close: Jun 6
$7.11
0
[0.00%]
After Hours: 4:00PM EDT
Why is it moving?
Replimune Group shares are trading higher after the company announced the topline results from the primary analysis of the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma.
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Replimune Group Stock (NASDAQ:REPL)
Replimune Group Stock (NASDAQ: REPL)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, June 06, 2024
S&P 500 Edges Lower; J. M. Smucker Shares Sur...
Avi Kapoor
-
1 hour ago
Why G-III Apparel Shares Are Trading Lower By...
Avi Kapoor
-
2 hours ago
12 Health Care Stocks Moving In Thursday's In...
Benzinga Insights
-
3 hours ago
Crude Oil Jumps 2%; Lululemon Posts Upbeat Ea...
Avi Kapoor
-
3 hours ago
Why Is Mid-Cap Cancer-Focused Replimune Stock...
Vandana Singh
-
3 hours ago
J.M. Smucker Posts Upbeat Earnings, Joins Tor...
Avi Kapoor
-
5 hours ago
Replimune Group shares are trading higher aft...
Benzinga Newsdesk
-
5 hours ago
Replimune Says Topline Results From Primary ...
Benzinga Newsdesk
-
8 hours ago
Monday, June 03, 2024
Replimune Group shares are trading higher aft...
Benzinga Newsdesk
-
3 days ago
Replimune To Present Data From RP1 And RP2 Cl...
Benzinga Newsdesk
-
3 days ago
Thursday, May 16, 2024
Replimune Group Inc. Expects Enrollment Of Fi...
Benzinga Newsdesk
-
May 16, 2024, 8:11AM
Monday, April 08, 2024
Replimune Group Presented The Interim Results...
Benzinga Newsdesk
-
Apr 8, 2024, 2:21AM
Tuesday, March 26, 2024
Replimune Appoints Sushil Patel To CEO Succee...
Benzinga Newsdesk
-
Mar 26, 2024, 7:35AM
Thursday, February 08, 2024
Replimune Group: Q3 Earnings Insights
Benzinga Insights
-
Feb 8, 2024, 8:10AM
Replimune Group Q3 EPS $(0.77) Beats $(0.93) ...
Benzinga Newsdesk
-
Feb 8, 2024, 8:03AM
Wednesday, December 06, 2023
Barclays Maintains Overweight Rating for Repl...
Benzinga Insights
-
Dec 6, 2023, 12:00PM
Barclays Maintains Overweight on Replimune Gr...
Benzinga Newsdesk
-
Dec 6, 2023, 6:36AM
Tuesday, December 05, 2023
Crude Oil Moves Lower; AutoZone Profit Tops V...
Lisa Levin
-
Dec 5, 2023, 2:27PM
Why Daktronics Shares Are Trading Lower By Ov...
Lisa Levin
-
Dec 5, 2023, 1:06PM
12 Health Care Stocks Moving In Tuesday's Int...
Benzinga Insights
-
Dec 5, 2023, 12:31PM
Dow Falls 100 Points; ISM Services PMI Increa...
Lisa Levin
-
Dec 5, 2023, 12:11PM
US Stocks Down; JM Smucker Posts Upbeat Earni...
Lisa Levin
-
Dec 5, 2023, 9:39AM
Replimmune shares are trading lower after the...
Benzinga Newsdesk
-
Dec 5, 2023, 8:57AM
What's Going On With Cancer-Focused Replimune...
Vandana Singh
-
Dec 5, 2023, 8:49AM
12 Health Care Stocks Moving In Tuesday's Pre...
Benzinga Insights
-
Dec 5, 2023, 8:07AM
Replimune Shares Initial Primary Analysis Res...
Benzinga Newsdesk
-
Dec 5, 2023, 7:01AM
Monday, November 13, 2023
HC Wainwright & Co. Maintains Buy on Replimun...
Benzinga Newsdesk
-
Nov 13, 2023, 6:07PM
Wednesday, November 08, 2023
Wedbush Reiterates Outperform on Replimune Gr...
Benzinga Newsdesk
-
Nov 8, 2023, 9:14AM
Replimune Presents Updated Data On RP2 In Uve...
Benzinga Newsdesk
-
Nov 8, 2023, 9:14AM
Tuesday, November 07, 2023
8 Health Care Stocks Whale Activity In Today'...
Benzinga Insights
-
Nov 7, 2023, 12:35PM
Replimune Group Q2 EPS $(0.90) Misses $(0.86)...
Benzinga Newsdesk
-
Nov 7, 2023, 8:06AM
Tuesday, September 19, 2023
Replimune Announces Appointment Of Emily Hill...
Benzinga Newsdesk
-
Sep 19, 2023, 8:07AM
Monday, August 07, 2023
HC Wainwright & Co. Maintains Buy on Replimun...
Benzinga Newsdesk
-
Aug 7, 2023, 6:22AM
Thursday, August 03, 2023
Replimune Group shares are trading lower. The...
Benzinga Newsdesk
-
Aug 3, 2023, 3:03PM
Replimune Group Q1 EPS $(0.75) Beats $(0.85) ...
Happy Mohamed
-
Aug 3, 2023, 8:17AM
Tuesday, August 01, 2023
The Latest Analyst Ratings for Replimune Grou...
Benzinga Insights
-
Aug 1, 2023, 11:00AM
HC Wainwright & Co. Reiterates Buy on Replimu...
Benzinga Newsdesk
-
Aug 1, 2023, 6:15AM
Monday, July 31, 2023
Replimune And Incyte Enter Into Clinical Tria...
Happy Mohamed
-
Jul 31, 2023, 4:25PM
Thursday, June 15, 2023
JP Morgan Maintains Overweight on Replimune G...
Benzinga Newsdesk
-
Jun 15, 2023, 8:10AM
Thursday, June 08, 2023
HC Wainwright & Co. Reiterates Buy on Replimu...
Benzinga Newsdesk
-
Jun 8, 2023, 6:14AM
Wednesday, June 07, 2023
Analyst Ratings for Replimune Group
Benzinga Insights
-
Jun 7, 2023, 9:00AM
Wedbush Reiterates Outperform on Replimune Gr...
Benzinga Newsdesk
-
Jun 7, 2023, 8:17AM
EF Hutton Reiterates Buy on Replimune Group, ...
Benzinga Newsdesk
-
Jun 7, 2023, 4:11AM
Monday, June 05, 2023
12 Health Care Stocks Moving In Monday's Intr...
Benzinga Insights
-
Jun 5, 2023, 1:31PM
Why Amedisys Shares Are Trading Higher By 14%...
Lisa Levin
-
Jun 5, 2023, 1:09PM
Replimune Group shares are trading higher on ...
Benzinga Newsdesk
-
Jun 5, 2023, 12:15PM
Director at Replimune Group Acquires Company ...
Benzinga Insights
-
Jun 5, 2023, 11:00AM
HC Wainwright & Co. Maintains Buy on Replimun...
Benzinga Newsdesk
-
Jun 5, 2023, 6:21AM
EF Hutton Reiterates Buy on Replimune Group, ...
Benzinga Newsdesk
-
Jun 5, 2023, 4:07AM
Saturday, June 03, 2023
Replimune Presented RP1 Data From The IGNYTE ...
Charles Gross
-
Jun 3, 2023, 2:43PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch